Southwest Synthetic Pharmaceutical Restructures
This article was originally published in PharmAsia News
Executive Summary
Southwest Synthetic Pharmaceutical will issue 41 million shares to Peking University International Hospital to acquire the latter's 90.63 percent stake in Chongqing Daxin Pharmaceutical at 5.36 yuan per share. After the equity issuance estimated at 220 million yuan, Peking University International Hospital will hold 50.50 percent of Southwest Synthetic's total shares. Chongqing Daxin's major products are Lovastatin, Mycophenolic Acid, Tobramycin and Amikacin Sulfate, which are mainly exported to overseas markets. Recognized globally for its quality and standards, the firm will represent a strong asset to Southwest Synthetic. (Click here for more - Chinese Language)